EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioRestorative Therapies's Enterprise Value is €-2.98 Mil.
BioRestorative Therapies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-10.16 Mil. Therefore, BioRestorative Therapies's EV-to-FCF for today is 0.29.
The historical rank and industry rank for BioRestorative Therapies's EV-to-FCF or its related term are showing as below:
FRA:9OF'
s EV-to-FCF Range Over the Past 10 Years
Min: -26.25 Med: -1.59 Max: 2.61
Current: 0.29
During the past 13 years, the highest EV-to-FCF of BioRestorative Therapies was 2.61. The lowest was -26.25. And the median was -1.59.
FRA:9OF's EV-to-FCF is ranked better than 90.63% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs FRA:9OF: 0.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioRestorative Therapies's PE Ratio (TTM) for today is calculated as:
BioRestorative Therapies's share price for today is €0.314.
BioRestorative Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.918.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioRestorative Therapies EV-to-FCF Related Terms
BioRestorative Therapies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioRestorative Therapies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's EV-to-FCF falls into.
BioRestorative Therapies's current Enterprise Value is €-2.98 Mil.
BioRestorative Therapies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a EV-to-FCF of 0.29 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #31 out of 331 companies in the Biotechnology industry, placing it in the top 9.4%.
Is BioRestorative Therapies' EV-to-FCF too high?
BioRestorative Therapies' current EV-to-FCF is 0.29. The Biotechnology industry median EV-to-FCF is 15.90. BioRestorative Therapies' value of 0.29 is 98.2% below this industry median. Based on the distribution chart, BioRestorative Therapies ranks #31 out of 331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' EV-to-FCF compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #31 out of 331 companies for EV-to-FCF. This places BioRestorative Therapies in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.90. BioRestorative Therapies' value of 0.29 is 98.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current EV-to-FCF of 0.29 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current EV-to-FCF is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.26, compared to a current price of €0.31 — trading 75.1% below its estimated fair value. The current EV-to-FCF is 0.29 and 98.2% below the Biotechnology industry median of 15.90. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current EV-to-FCF is 0.29 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.31 is trading 75.1% below its estimated GF Value™ of €1.26.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
EV-to-FCF: 0.29
GF Value™: €1.26 vs. price of €0.31 (75.1% below fair value)
Industry Position: 98.2% below the Biotechnology median (#31 of 331)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for FRA:9OF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
